emendo biotherapeutics

Emendo Biotherapeutics

Business Overview

Acquired
Operating Status
May 2015
Founded
47
Employees
Description
Emendo is a genome editing company developing genetic medicines and cell therapies for severe diseases. Emendo's cutting-edge technology is based on its proprietary protein engineering and selection platforms, designed to generate ultra-specific and highly active CRISPR OMNI nucleases, carefully optimized per target sequence for generating safe and effective genetic solution. Emendo was established in 2015 with investments by OrbiMed Advisors LLP And Takeda Ventures, Inc. the corporate venture arm of Takeda Pharmaceuticals Limited.
Sectors

Founders

Investors

Investor

Investor Type

Series Preference

Seed, Series A, Series B, Series C, Series D
Series A, Series B

Funding Rounds

$61,000,000
Total Funding

1

Funding Rounds
Series B
Last Funding Series

Date Announced

Funding Round

Amount Raised

Investors

Exit Events and Acquisitions

Date Announced

Transaction

Consideration

Target

Acquirer

AI Technology Stack™

AI Team Size
1
AI Technologies
AI Technologies

© 2021 StartupHub.ai. All rights reserved.

You cannot copy content of this page

Sign up for free

  • Save profiles to your list
  • Basic search functionality

Sign up to keep browsing

You reached your pageview limit

  • Save profiles to your list
  • Basic search functionality
  • Browse our leading AI database